June 2018 Meeting in San Francisco
TOPIC: Mapping the 3-Dimensional Hydration Content and Changes in the Stratum Corneum
Applying topical conditioning agents is common practice for managing xerosis (abnormal dryness of the skin, mucous membranes, or conjunctiva (xerophthalmia)) and other skin conditions both in the office and at home. Here, Rodan + Fields investigated changes in moisture content and thickness of the Stratum Corneum (SC) and Stratum Disjunctum (SD) and changes in moisture below SC/SD following application of a commercial skin conditioning serum, referred to as 3D3P-IPN (1).
This talk will review the experimental design, and their develpoment of 3-dimensional model of changes in moisture content in upper layers of the epidermis as a function of product application. The formulation developed employs a novel combination of sodium hyaluronate, a water-binding polysaccharide, a blend of ceramides, glycerol, an alky-modified cellulosic gum and a crosslinked polysaccharide. They have found this system improves overall barrier function, dermal thickness, moisture content and lipid ordering by delivering humectants throughout the outer most layers of skin, providing lasting relief from xerosis and skin dryness.
Dr. Robert (Bob) J. Bianchini was previously with Merck & Co. where he was Vice-President of R&D, Consumer Care. He led the development and global expansion of its major Dermatology brands. Bob's technical team invented new OTC Skin Protection Products as well as novel topical delivery systems. He managed the development activities for Coppertone, A&D, Elocon, Tri-derm, Lotrimin, and Tinactin. Prior to Merck& Co., Bob held executive positions at Johnson & Johnson and Colgate-Palmolive. Bob’s tenure at J&J included increasing responsibility in Global Skin Care and Advanced Technologies for the Consumer Division. His team developed many Aveeno, Neutrogena and Clean and Clear skin care products. Under his thoughtful leadership, he initiated a technology effort which led to breakthrough performance in Johnson’s No More Tear’s baby shampoo. He also obtained funding for the Division’s first Internal Venture. He completed his tenure as Chief Scientific Officer of a Johnson & Johnson Development Corporation Venture, Molsaic, chartered with discovering innovative binding sequences for coupling affinity peptides with active ingredients to biological surfaces. Dr. Bianchini received his Ph.D. in Chemistry from Washington State University, Pullman, WA and undergraduate degrees in Chemistry and Biology from SUNY. He completed Post Graduate Training at Northwestern University and M.I.T. He has authored over 25 patents and publications and has lectured globally on the importance of OTC medicines and personal hygiene products for optimal health and wellness. He is a member of The American Association of Pharmaceutical Scientists, The American Academy of Dermatology, The American Chemical Society, The Scientific Advisory Board for the Personal Care Products Council, Washington, D.C., and a former member of the Board of Trustees at TRI Princeton, Princeton, NJ.
|Event Date||June 12, 2018 6:00 pm|
|Event End Date||June 12, 2018 10:00 pm|